Business Context and Reporting Period
Company: Mereo Biopharma Group Plc (MREO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Mereo is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases. Its core portfolio includes setrusumab for osteogenesis imperfecta (OI), alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), and vantictumab for autosomal dominant osteopetrosis Type 2 (ADO2). The company relies on strategic partnerships for development and commercialization, retaining rights in specific territories (e.g., Europe/UK) while licensing others globally.
Key Financial Metrics
| Metric ($ in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $500 | $0 |
| Net Loss | $(41,878) | $(43,253) |
| Research & Development Expenses | $(17,766) | $(20,930) |
| General & Administrative Expenses | $(23,008) | $(26,434) |
| Cash and Cash Equivalents (Year End) | $40,992 | $69,802 |
| Accumulated Deficit | $(501,018) | $(462,883) |
| Net Cash Used in Operating Activities | $(30,971) | $(32,834) |
Note: The company has never generated revenue from product sales. The $0.5 million revenue in 2025 was a milestone payment from a licensing partner.
Material Changes vs. Prior Period
- Revenue Recognition: The company recognized $0.5 million in revenue in 2025 from a clinical milestone payment received from ReproNovo for leflutrozole, compared to zero revenue in 2024.
- Expense Reductions: Total operating expenses decreased by approximately $6.6 million. R&D expenses declined by $3.2 million, primarily due to reduced spending on alvelestat ($7.7 million decrease) and etigilimab ($1.0 million decrease), partially offset by increased setrusumab costs ($5.7 million increase) related to manufacturing agreements with Ultragenyx.
- Foreign Exchange Impact: A significant foreign currency transaction loss of $6.3 million was recorded in 2025 due to the weakening of the U.S. dollar against the pound sterling, compared to a gain of $1.2 million in 2024.
- Debt Conversion: The Novartis convertible loan note ($5.5 million carrying value) was fully converted into equity in February 2025, eliminating interest-bearing debt and reducing interest expense by $1.1 million.
Guidance, Outlook, and Risks
Clinical Developments and Outlook
- Setrusumab (OI): On December 29, 2025, the company announced top-line results from Phase 3 Orbit and Cosmic studies. Neither study achieved statistical significance against primary endpoints (reduction in annualized clinical fracture rate) compared to placebo or bisphosphonates. However, both studies met secondary endpoints showing statistically significant improvements in Bone Mineral Density (BMD). The company is analyzing data to determine next steps, including potential regulatory interactions.
- Alvelestat (AATD-LD): The company is preparing for a potential Phase 3 study and evaluating non-dilutive financing options.
- Liquidity: Management believes existing cash resources ($41.0 million as of Dec 31, 2025) are sufficient to fund operations into mid-2027. Additional funding will be required thereafter to complete development plans.
Material Risks and Contingencies
- Nasdaq Listing Compliance: On February 17, 2026, the company received notice from Nasdaq that its ADSs failed to maintain the minimum $1.00 bid price requirement. The company has 180 days (until August 17, 2026) to regain compliance or face delisting.
- Legal Proceedings: A putative securities class action lawsuit was filed on February 4, 2026, alleging false and misleading statements regarding the company's business. The company intends to vigorously defend the action.
- Capital Requirements: The company has an accumulated deficit of $501.0 million and expects to continue incurring significant operating losses. Failure to raise additional capital could force delays or elimination of R&D programs.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2027" liquidity projection given the recent $28.8 million decrease in cash and cash equivalents during 2025.
- Setrusumab Regulatory Path: Monitor upcoming regulatory interactions regarding the Phase 3 data, specifically how the lack of primary endpoint success but positive BMD data will impact approval strategies in the EU and UK.
- Nasdaq Compliance: Track the ADS trading price to ensure it meets the $1.00 threshold for 10 consecutive days before the August 17, 2026 deadline to avoid delisting.
- Legal Exposure: Review the status of the February 2026 securities class action lawsuit for potential financial impact or settlement discussions.
- Partnership Dependencies: Assess the financial stability and performance of key partners (Ultragenyx, AstraZeneca, ReproNovo) given the company's reliance on them for development funding and commercialization.